Literature DB >> 17098770

Herpes simplex virus type 2: epidemiology and management options in developing countries.

G Paz-Bailey1, M Ramaswamy, S J Hawkes, A M Geretti.   

Abstract

Genital herpes simplex virus type 2 (HSV2) is highly prevalent worldwide and an increasingly important cause of genital ulcer disease (GUD). Continued HSV2 transmission is facilitated by the large number of undiagnosed cases, the frequency of atypical disease and the occurrence of asymptomatic shedding. The lack of easy, affordable diagnostic methods and specific antiviral treatment in countries with low and middle income is of great concern, given the ability of GUD to enhance HIV transmission and acquisition. With rising HSV2 prevalence contributing to an increase in the proportion of GUD attributed to genital herpes in high-HIV prevalence settings, a safe and effective HSV vaccine is urgently needed. Meanwhile, multifaceted interventions are required to improve recognition of genital herpes, to prevent its spread and also to prevent its potential to promote HIV transmission in developing countries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17098770      PMCID: PMC2598582          DOI: 10.1136/sti.2006.020966

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  70 in total

1.  Prior herpes simplex virus type 2 infection as a risk factor for HIV infection.

Authors:  S D Holmberg; J A Stewart; A R Gerber; R H Byers; F K Lee; P M O'Malley; A J Nahmias
Journal:  JAMA       Date:  1988-02-19       Impact factor: 56.272

2.  Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men.

Authors:  D W Cameron; J N Simonsen; L J D'Costa; A R Ronald; G M Maitha; M N Gakinya; M Cheang; J O Ndinya-Achola; P Piot; R C Brunham
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

3.  Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa.

Authors:  W Lai; C Y Chen; S A Morse; Ye Htun; H G Fehler; H Liu; R C Ballard
Journal:  Sex Transm Infect       Date:  2003-06       Impact factor: 3.519

4.  The etiology of genital ulceration in Rwanda.

Authors:  J Bogaerts; C A Ricart; E Van Dyck; P Piot
Journal:  Sex Transm Dis       Date:  1989 Jul-Sep       Impact factor: 2.830

5.  Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India.

Authors:  Steven J Reynolds; Arun R Risbud; Mary E Shepherd; Jonathan M Zenilman; Ronald S Brookmeyer; Ramesh S Paranjape; Anand D Divekar; Raman R Gangakhedkar; Manisha V Ghate; Robert C Bollinger; Sanjay M Mehendale
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

6.  Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.

Authors:  Timothy Schacker; Judith Zeh; Huilin Hu; Mary Shaughnessy; Lawrence Corey
Journal:  J Infect Dis       Date:  2002-11-22       Impact factor: 5.226

7.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors:  Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

8.  Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities.

Authors:  Hinda J Ahmed; Judica Mbwana; Eva Gunnarsson; Karin Ahlman; Chalamilla Guerino; Liselott A Svensson; Fred Mhalu; Teresa Lagergard
Journal:  Sex Transm Dis       Date:  2003-02       Impact factor: 2.830

9.  A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level.

Authors:  Patty W Wright; Craig J Hoesley; Kathleen E Squires; Angela Croom-Rivers; Heidi L Weiss; John W Gnann
Journal:  Clin Infect Dis       Date:  2003-01-06       Impact factor: 9.079

10.  Genital ulceration as a risk factor for human immunodeficiency virus infection.

Authors:  R M Greenblatt; S A Lukehart; F A Plummer; T C Quinn; C W Critchlow; R L Ashley; L J D'Costa; J O Ndinya-Achola; L Corey; A R Ronald
Journal:  AIDS       Date:  1988-02       Impact factor: 4.177

View more
  39 in total

1.  Genetic Diversity within Alphaherpesviruses: Characterization of a Novel Variant of Herpes Simplex Virus 2.

Authors:  Sonia Burrel; Nathalie Désiré; Julien Marlet; Laurent Dacheux; Sophie Seang; Eric Caumes; Hervé Bourhy; Henri Agut; David Boutolleau
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

2.  In Vitro and In Vivo Activity, Tolerability, and Mechanism of Action of BX795 as an Antiviral against Herpes Simplex Virus 2 Genital Infection.

Authors:  James Hopkins; Tejabhiram Yadavalli; Rahul Suryawanshi; Farreh Qatanani; Ipsita Volety; Ram Koganti; Aqsa Iqbal; Deepak Shukla
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 3.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

4.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

5.  [Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs].

Authors:  R Brans
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

6.  Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.

Authors:  Richard Brans; Feng Yao
Journal:  BMC Microbiol       Date:  2010-06-03       Impact factor: 3.605

7.  Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.

Authors:  Richard Brans; Natali V Akhrameyeva; Feng Yao
Journal:  J Invest Dermatol       Date:  2009-04-09       Impact factor: 8.551

8.  A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya.

Authors:  V Chohan; J M Baeten; S Benki; S M Graham; L Lavreys; K Mandaliya; J O Ndinya-Achola; W Jaoko; J Overbaugh; R S McClelland
Journal:  Sex Transm Infect       Date:  2009-05-19       Impact factor: 3.519

9.  Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism.

Authors:  Sonia Burrel; Zaïna Ait-Arkoub; Delphine Voujon; Claire Deback; Emiliana P Abrao; Henri Agut; David Boutolleau
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

Review 10.  Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention.

Authors:  Elena Anzivino; Daniela Fioriti; Monica Mischitelli; Anna Bellizzi; Valentina Barucca; Fernanda Chiarini; Valeria Pietropaolo
Journal:  Virol J       Date:  2009-04-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.